News/ News/ R&D Mereo’s brittle bone drug likely to shrug off phase 2b fail, say analysts Phil Taylor Mereo, osteogenesis imperfecta, rare disease 0 Comment Mereo’s drug candidate for brittle bone disease missed its primary endpoint in a recent phase 2b study, but Share X Mereo’s brittle bone drug likely to shrug off phase 2b fail, say analysts https://pharmaphorum.com/news/mereos-brittle-bone-drug-likely-to-shrug-off-phase-2b-fail-say-analysts/
News/ News/ R&D UK biotech Mereo gears up for key brittle bone drug data Richard Staines Mereo Biopharma, osteogenesis imperfecta, Rare diseases 0 Comment UK biotech Mereo BioPharma is hoping the coming months will transform its fortunes as it prepares for potentially Share X UK biotech Mereo gears up for key brittle bone drug data https://pharmaphorum.com/news/uk-biotech-mereo-gears-up-for-key-brittle-bone-drug-data/
